Rep. Josh Gottheimer Sells Edwards Lifesciences Corporation (NYSE:EW) Shares

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Edwards Lifesciences Corporation (NYSE:EW). In a filing disclosed on December 29th, the Representative disclosed that they had sold between $1,001 and $15,000 in Edwards Lifesciences stock on November 19th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Dassault Systemes (OTCMKTS:DASTY) on 11/21/2025.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 11/19/2025.
• Sold $1,001 – $15,000 in shares of HubSpot (NYSE:HUBS) on 11/19/2025.
• Sold $15,001 – $50,000 in shares of Fidelity National Information Services (NYSE:FIS) on 11/19/2025.
• Sold $1,001 – $15,000 in shares of KKR & Co. Inc. (NYSE:KKR) on 11/19/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 11/19/2025.
• Purchased $1,001 – $15,000 in shares of CSW Industrials (NYSE:CSW) on 11/17/2025.
• Sold $1,001 – $15,000 in shares of 3M (NYSE:MMM) on 10/20/2025.
• Purchased $1,001 – $15,000 in shares of NiCE (NASDAQ:NICE) on 10/17/2025.
• Purchased $1,001 – $15,000 in shares of NetEase (NASDAQ:NTES) on 10/17/2025.

Edwards Lifesciences Price Performance

EW opened at $85.26 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. The company has a market capitalization of $49.48 billion, a price-to-earnings ratio of 36.75, a P/E/G ratio of 3.87 and a beta of 0.97. The firm’s fifty day moving average price is $84.45 and its two-hundred day moving average price is $79.83. Edwards Lifesciences Corporation has a 1 year low of $65.94 and a 1 year high of $87.89.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The company had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the prior year, the company posted $0.67 earnings per share. The firm’s revenue for the quarter was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. As a group, analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 11,386 shares of Edwards Lifesciences stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $83.76, for a total transaction of $953,691.36. Following the completion of the sale, the vice president owned 38,970 shares in the company, valued at approximately $3,264,127.20. This trade represents a 22.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Daniel J. Lippis sold 1,020 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $82.55, for a total value of $84,201.00. Following the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,816,265.10. The trade was a 4.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 45,465 shares of company stock worth $3,804,610 in the last ninety days. 1.29% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Several large investors have recently added to or reduced their stakes in EW. Vanguard Group Inc. boosted its holdings in Edwards Lifesciences by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock valued at $5,472,147,000 after purchasing an additional 365,581 shares during the period. Wellington Management Group LLP raised its position in shares of Edwards Lifesciences by 4.9% in the third quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company’s stock worth $1,617,959,000 after buying an additional 977,933 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Edwards Lifesciences by 8.1% during the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after buying an additional 1,423,365 shares during the period. Jennison Associates LLC boosted its stake in Edwards Lifesciences by 19.6% during the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock valued at $1,085,574,000 after buying an additional 2,287,783 shares during the period. Finally, Geode Capital Management LLC grew its position in Edwards Lifesciences by 0.4% during the second quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company’s stock worth $990,074,000 after buying an additional 45,555 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the subject of several analyst reports. Stifel Nicolaus set a $100.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Friday, December 5th. JPMorgan Chase & Co. raised Edwards Lifesciences from a “neutral” rating to an “overweight” rating and increased their price target for the company from $90.00 to $100.00 in a research report on Thursday, December 18th. Jefferies Financial Group set a $98.00 price objective on Edwards Lifesciences and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Wall Street Zen downgraded Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. Finally, The Goldman Sachs Group set a $104.00 target price on Edwards Lifesciences and gave the stock a “buy” rating in a research note on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $93.95.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.